More:    MJNA HOME        CANNABIS NEWS        SHOP        CONTACT 

  • Dashboard
  • Reports & Disclosure
  • Financial Results
  • Shareholder
    • Shareholder Information
    • Shareholder Rewards
  • News
    • Media Coverage
    • Press Releases
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Dashboard
  • Reports & Disclosure
  • Financial Results
  • Shareholder
    • Shareholder Information
    • Shareholder Rewards
  • News
    • Media Coverage
    • Press Releases
Medical Marijuana, Inc. CEO to Present on CBD Safety at Sixth Annual New York Cannabis World Congress; Subsidiary HempMeds® to Exhibit New CBD Products

Medical Marijuana, Inc. CEO to Present on CBD Safety at Sixth Annual New York Cannabis World Congress; Subsidiary HempMeds® to Exhibit New CBD Products

by adminAdrianRamirez | May 29, 2019 | HempMeds, Press Releases

SAN DIEGO, May 29, 2019 — Medical Marijuana, Inc.(OTC:MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply...
Medical Marijuana, Inc. Subsidiary Kannaway® Announces First-Ever Authorization in Bulgaria to Sell Hemp-Derived CBD Products

Medical Marijuana, Inc. Subsidiary Kannaway® Announces First-Ever Authorization in Bulgaria to Sell Hemp-Derived CBD Products

by adminAdrianRamirez | May 28, 2019 | Kannaway, Press Releases

SAN DIEGO, May 28, 2019 — Medical Marijuana, Inc. (OTC:MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply...
Medical Marijuana, Inc. Portfolio Company Kannalife, Inc. Publishes New Research on CBD and Chemotherapy-Induced Peripheral Neuropathy

Medical Marijuana, Inc. Portfolio Company Kannalife, Inc. Publishes New Research on CBD and Chemotherapy-Induced Peripheral Neuropathy

by adminAdrianRamirez | May 23, 2019 | Kannalife Sciences, Press Releases

SAN DIEGO, May 23, 2019 — Medical Marijuana, Inc. (OTC:MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply...
Medical Marijuana, Inc. Reports Over $20.2M in Revenue in Q1 2019, Up 92% Year-Over-Year in Financial Results

Medical Marijuana, Inc. Reports Over $20.2M in Revenue in Q1 2019, Up 92% Year-Over-Year in Financial Results

by adminAdrianRamirez | May 22, 2019 | Press Releases

SAN DIEGO, May 22, 2019 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today its financial results for the quarter ending March 31, 2019, and provided an overview of recent operational...
Medical Marijuana, Inc. CEO Chosen to Present Oral Comments at FDA’s Public Hearing on Products Containing Cannabis and Cannabis-Derived Compounds

Medical Marijuana, Inc. CEO Chosen to Present Oral Comments at FDA’s Public Hearing on Products Containing Cannabis and Cannabis-Derived Compounds

by adminAdrianRamirez | May 21, 2019 | Press Releases

SAN DIEGO, May 21, 2019 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, announced today that the Company’s CEO, Dr. Stuart Titus, has been chosen as one of 65 speakers to present oral comments at...
« Older Entries
Next Entries »

Recent Posts

  • Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
  • Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New Full Spectrum Concentrations in Brazil With Competitive Price Point
  • Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team With Appointment of Industry Veterans to Roles of Executive Vice President and Vice President of Information Technology
  • Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Celebrates Major Features Across Several Marquee Brazilian Press Outlets
  • Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Participates in Research Finding Promising Therapeutic Benefits of CBD in Parkinson’s Disease Treatment

Recent Comments

No comments to show.

Home     Company    Education     Careers     Shop

This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Food and Drug Administration (FDA) Disclosure

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Leaving Our Website Disclaimer: If we have a research link to a website where we sell products or have product information you are now leaving the medicalmarijuanainc.com website. Links to any informational websites are provided solely as a service to our users.

The link provides additional information that may be useful or interesting and has no aliation to the promotion, sale and distribution of Medical Marijuana Inc. products. The link does not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.

* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.

© 2021 Medical Marijuana, Inc. All Rights Reserved.